Medtronic plc (NYSE:MDT - Get Free Report) traded down 0.3% during mid-day trading on Wednesday . The stock traded as low as $89.22 and last traded at $89.42. 1,331,132 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 6,166,881 shares. The stock had previously closed at $89.68.
MDT has been the topic of several research analyst reports. Citigroup lifted their price objective on shares of Medtronic from $85.00 to $92.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 1st. Oppenheimer lifted their price objective on shares of Medtronic from $92.00 to $94.00 and gave the stock a "market perform" rating in a research report on Wednesday, August 21st. Stifel Nicolaus lifted their price objective on shares of Medtronic from $85.00 to $87.00 and gave the stock a "hold" rating in a research report on Wednesday, August 21st. Royal Bank of Canada upgraded shares of Medtronic from a "sector perform" rating to an "outperform" rating and lifted their price objective for the stock from $98.00 to $105.00 in a research report on Thursday, October 10th. Finally, Daiwa America upgraded shares of Medtronic to a "strong-buy" rating in a research report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $95.36.
View Our Latest Report on MDT
The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13. The firm's 50 day moving average is $89.69 and its 200-day moving average is $84.38. The firm has a market cap of $115.54 billion, a price-to-earnings ratio of 30.44, a price-to-earnings-growth ratio of 2.55 and a beta of 0.84.
Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.03. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The business had revenue of $7.97 billion during the quarter, compared to analyst estimates of $7.90 billion. During the same quarter in the previous year, the business earned $1.20 EPS. Medtronic's quarterly revenue was up 3.4% compared to the same quarter last year. Sell-side analysts anticipate that Medtronic plc will post 5.44 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, October 11th. Shareholders of record on Friday, September 27th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend was Friday, September 27th. Medtronic's dividend payout ratio is 94.59%.
Institutional investors and hedge funds have recently bought and sold shares of the company. Manning & Napier Advisors LLC acquired a new position in Medtronic during the 2nd quarter worth $25,643,000. SageView Advisory Group LLC raised its position in shares of Medtronic by 130.3% during the first quarter. SageView Advisory Group LLC now owns 16,829 shares of the medical technology company's stock valued at $1,467,000 after buying an additional 9,523 shares during the last quarter. Empowered Funds LLC raised its position in shares of Medtronic by 174.9% during the first quarter. Empowered Funds LLC now owns 74,903 shares of the medical technology company's stock valued at $6,528,000 after buying an additional 47,657 shares during the last quarter. National Bank of Canada FI raised its position in shares of Medtronic by 13.6% during the first quarter. National Bank of Canada FI now owns 261,325 shares of the medical technology company's stock valued at $21,642,000 after buying an additional 31,195 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Medtronic by 6.3% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 368,682 shares of the medical technology company's stock valued at $29,019,000 after buying an additional 21,995 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.